A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given
rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been
exposed to anthracycline therapy, using a fixed dose-escalation schema every 21 days to
establish the maximum tolerated dose (MTD) of the combination of NOX66 and doxorubicin.